덴마크 -
덴마크어 -
Lægemiddelstyrelsen (Danish Medicines Agency)
salofalk 500 mg enterodepotgranulat, breve
dr. falk pharma gmbh - mesalazin - enterodepotgranulat, breve - 500 mg
덴마크 -
덴마크어 -
Lægemiddelstyrelsen (Danish Medicines Agency)
salofalk 4 g/60 ml rektalvæske, suspension
dr. falk pharma gmbh - mesalazin - rektalvæske, suspension - 4 g/60 ml
유럽 연합 -
덴마크어 -
EMA (European Medicines Agency)
jorveza
dr. falk pharma gmbh - budesonide - esophageal sygdomme - antidiarrémidler, tarm antiinflammatorisk / antiinfective agenter - jorveza er indiceret til behandling af eosinofiløsofagitis (eoe) hos voksne (over 18 år).
덴마크 -
덴마크어 -
Lægemiddelstyrelsen (Danish Medicines Agency)
nyvigan 100000 ie/g+100000ie salve + vaginaltabletter
dr. pfleger arzneimittel gmbh - nystatin - salve + vaginaltabletter - 100000 ie/g+100000ie
덴마크 -
덴마크어 -
Lægemiddelstyrelsen (Danish Medicines Agency)
axhidrox 2,2 mg/dosis creme
dr. august wolff gmbh & co. kg arzneimittel - glycopyrroniumbromid - creme - 2,2 mg/dosis
덴마크 -
덴마크어 -
Lægemiddelstyrelsen (Danish Medicines Agency)
budenofalk 9 mg enterogranulat
dr. falk pharma gmbh - budesonid - enterogranulat - 9 mg
덴마크 -
덴마크어 -
Lægemiddelstyrelsen (Danish Medicines Agency)
dormidina 12,5 mg filmovertrukne tabletter
laboratorios dr. esteve., s.a. - doxylaminhydrogensuccinat - filmovertrukne tabletter - 12,5 mg
덴마크 -
덴마크어 -
Lægemiddelstyrelsen (Danish Medicines Agency)
dormidina 25 mg filmovertrukne tabletter
laboratorios dr. esteve., s.a. - doxylaminhydrogensuccinat - filmovertrukne tabletter - 25 mg
덴마크 -
덴마크어 -
Lægemiddelstyrelsen (Danish Medicines Agency)
salofalk 1000 mg enterodepotgranulat, breve
dr. falk pharma gmbh - mesalazin - enterodepotgranulat, breve - 1000 mg
유럽 연합 -
덴마크어 -
EMA (European Medicines Agency)
budesonide/formoterol teva pharma b.v.
teva pharma b.v. - budesonide, formoterol - astma - medicin for obstruktiv sygdomme, - budesonid / formoterol teva pharma b. indikeres kun hos voksne 18 år og ældre. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.